{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:00:19Z","timestamp":1792699219890,"version":"4.5.0"},"reference-count":165,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T00:00:00Z","timestamp":1732406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.autrev.2024.103710","type":"journal-article","created":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T11:06:53Z","timestamp":1732446413000},"page":"103710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Intravenous immunoglobulin as a therapy for autoimmune conditions"],"prefix":"10.1016","volume":"24","author":[{"given":"Maria Giovanna","family":"Danieli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Gammeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Longhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Francesca","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Palmeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Gangemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2024.103710_bb0005","series-title":"Committee for Medicinal Products for human use (CHMP) guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg)","author":"CHMP, BPWP","year":"2021"},{"key":"10.1016\/j.autrev.2024.103710_bb0010","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1196\/annals.1361.118","article-title":"Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss","volume":"1051","author":"Sapir","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2024.103710_bb0015","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199412153312409","article-title":"Transmission of viral infections through intravenous immune globulin","volume":"331","author":"Schiff","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103710_bb0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2004.04.002","article-title":"The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile","volume":"102","author":"Dalakas","year":"2004","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.autrev.2024.103710_bb0025","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1567-5769(03)00134-6","article-title":"Comparison of the efficacy of IGIV-C, 10% (caprylate\/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency: A randomized double-blind trial","volume":"3","author":"Roifman","year":"2003","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2024.103710_bb0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJM199201093260206","article-title":"Manipulating the immune system with immune globulin","volume":"326","author":"Dwyer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103710_bb0035","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103710_bb0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1600-065X.1994.tb00858.x","article-title":"V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (iv Ig)","volume":"139","author":"Kazatchkine","year":"1994","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2024.103710_bb0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0161-5890(88)90088-0","article-title":"Immunoglobulin G dimer: an idiotype-anti-idiotype complex","volume":"25","author":"Tankersley","year":"1988","journal-title":"Mol Immunol"},{"key":"10.1016\/j.autrev.2024.103710_bb0050","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.4049\/jimmunol.144.4.1387","article-title":"A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG","volume":"144","author":"Roux","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2024.103710_bb0055","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1172\/JCI114483","article-title":"Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies","volume":"85","author":"Dietrich","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2024.103710_bb0060","first-page":"387","article-title":"Immunomodulatory action of intravenous immunoglobulin Immunology","volume":"107","author":"Sewell","year":"2002"},{"key":"10.1016\/j.autrev.2024.103710_bb0065","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198602063140601","article-title":"Microvascular deposition of complement membrane attack complex in dermatomyositis","volume":"314","author":"Kissel","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103710_bb0070","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J Clin Invest"},{"issue":"Suppl","key":"10.1016\/j.autrev.2024.103710_bb0075","first-page":"1","article-title":"High-dose intravenous immunoglobulin treatment of multiple sclerosis","volume":"23","author":"Durelli","year":"2002","journal-title":"Neurol Sci"},{"key":"10.1016\/j.autrev.2024.103710_bb0080","first-page":"336","article-title":"Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A meta-analysis","volume":"30","author":"Olyaeemanesh","year":"2016","journal-title":"Med J Islam Repub Iran"},{"key":"10.1016\/j.autrev.2024.103710_bb0085","first-page":"45","article-title":"Efgartigimod as a novel FcRn inhibitor for autoimmune disease","author":"Yang","year":"2024","journal-title":"Neurol Sci"},{"key":"10.1016\/j.autrev.2024.103710_bb0090","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature10134","article-title":"Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway","volume":"475","author":"Anthony","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2024.103710_bb0095","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.4049\/jimmunol.1301260","article-title":"Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production","volume":"192","author":"Tjon","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2024.103710_bb0100","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1189\/jlb.3VMA0315-078R","article-title":"Intravenous immunoglobulin skews macrophages to an anti-inflammatory, IL-10-producing activation state","volume":"98","author":"Kozicky","year":"2015","journal-title":"J Leucocyte Biol"},{"key":"10.1016\/j.autrev.2024.103710_bb0105","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.3389\/fimmu.2018.02676","article-title":"IVIg and LPS co-stimulation induces IL-10 production by human monocytes, which is compromised by an Fc\u03b3RIIA disease-associated gene variant","volume":"9","author":"Kozicky","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103710_bb0110","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2024.103710_bb0115","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1161\/CIRCRESAHA.112.266411","article-title":"Intravenous immunoglobulins modulate neutrophil activation and vascular injury through Fc\u03b3RIII and SHP-1","volume":"110","author":"Jang","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.autrev.2024.103710_bb0120","first-page":"275","article-title":"IgG Fc receptors","volume":"19","author":"Ravetch","year":"2003"},{"key":"10.1016\/j.autrev.2024.103710_bb0125","first-page":"715","article-title":"Expansion of CD4+ CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis","volume":"111","author":"Ephrem","year":"2008","journal-title":"Blood, J Am Soc Hematol"},{"key":"10.1016\/j.autrev.2024.103710_bb0130","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/(SICI)1521-4141(199806)28:06<1823::AID-IMMU1823>3.0.CO;2-F","article-title":"Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein","volume":"28","author":"Pashov","year":"1998","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2024.103710_bb0135","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3899\/jrheum.111123","article-title":"Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease","volume":"39","author":"Bayry","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2024.103710_bb0140","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jaci.2009.04.003","article-title":"Development and function of TH17 cells in health and disease","volume":"123","author":"Louten","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2024.103710_bb0145","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/nature07036","article-title":"Induction and effector functions of T(H)17 cells","volume":"453","author":"Bettelli","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2024.103710_bb0150","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaci.2010.12.1102","article-title":"Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin","volume":"127","author":"Maddur","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2024.103710_bb0155","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/art.38627","article-title":"Intravenous immunoglobulin attenuates experimental autoimmune arthritis by inducing reciprocal regulation of Th17 and Treg cells in an Interleukin-10\u2013dependent manner","volume":"66","author":"Lee","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103710_bb0160","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1067\/mai.2002.127284","article-title":"Suppression of IL-4-and CD40-induced B-lymphocyte activation by intravenous immunoglobulin is not mediated through the inhibitory IgG receptor Fc\u03b3RIIB","volume":"110","author":"Zhuang","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2024.103710_bb0165","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1182\/blood-2009-12-261461","article-title":"IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes","volume":"116","author":"S\u00e9\u00eft\u00e9","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2024.103710_bb0170","first-page":"133","article-title":"Intravenous immunoglobulin induces a functional silencing program similar to anergy in human B cells","author":"S\u00e9\u00eft\u00e9","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2024.103710_bb0175","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0022-3476(05)80900-X","article-title":"Effect of high doses of intravenously administered immune globulin on natural killer cell activity in peripheral blood","volume":"120","author":"Finberg","year":"1992","journal-title":"J Pediatr"},{"key":"10.1016\/j.autrev.2024.103710_bb0180","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/blood.V84.7.2136.2136","article-title":"Release of cytokines, soluble cytokine receptors, and Interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo","volume":"84","author":"Aukrust","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2024.103710_bb0185","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1172\/JCI116240","article-title":"Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment]","volume":"91","author":"Takei","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2024.103710_bb0190","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-018-0027-2","article-title":"Immune-mediated neuropathies","volume":"4","author":"Kieseier","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2024.103710_bb0195","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/mus.27922","article-title":"Updated consensus statement: intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee","volume":"68","author":"Tavee","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2024.103710_bb0200","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s13311-021-01108-4","article-title":"Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy","volume":"18","author":"Dalakas","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.autrev.2024.103710_bb0205","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1385\/CRIAI:29:3:281","article-title":"Intravenous immunoglobulin and Guillain-Barre syndrome","volume":"29","author":"Harel","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2024.103710_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11940-019-0569-y","article-title":"Immune-mediated neuropathies","volume":"21","author":"Fadia","year":"2019","journal-title":"Curr Treat Options Neurol"},{"issue":"9","key":"10.1016\/j.autrev.2024.103710_bb0215","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","volume":"2014","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2024.103710_bb0220","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ana.21737","article-title":"Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barr\u00e9 syndrome","volume":"66","author":"Kuitwaard","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2024.103710_bb0225","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/jnnp-2019-321496","article-title":"Original research: second IVIg course in Guillain-Barr\u00e9 syndrome with poor prognosis: the non-randomised ISID study","volume":"91","author":"Verboon","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2024.103710_bb0230","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1474-4422(20)30494-4","article-title":"Second intravenous immunoglobulin dose in patients with Guillain-Barr\u00e9 syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial","volume":"20","author":"Walgaard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2024.103710_bb0235","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejpn.2020.01.003","article-title":"Diagnosis and treatment of Guillain-Barr\u00e9 syndrome in childhood and adolescence: an evidence-and consensus-based guideline","volume":"25","author":"Korinthenberg","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.autrev.2024.103710_bb0240","first-page":"293","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: revisiting the role of intravenous immmunoglobulins","volume":"15","author":"Chapman","year":"2013","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.autrev.2024.103710_bb0245","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14737175.2022.2169134","article-title":"Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): mechanisms of action and clinical and genetic considerations","volume":"22","author":"Dalakas","year":"2022","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.autrev.2024.103710_bb0250","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2024.103710_bb0255","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/jns.12455","article-title":"European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision","volume":"26","author":"Van den Bergh","year":"2021","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.autrev.2024.103710_bb0260","first-page":"6","article-title":"Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study","author":"Van Schaik","year":"2019","journal-title":"Neurology(R) Neuroimmuno & Neuroinflammat"},{"key":"10.1016\/j.autrev.2024.103710_bb0265","first-page":"408","article-title":"Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?","author":"Allen","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2024.103710_bb0270","series-title":"Multifocal motor neuropathy","author":"Hameed","year":"2023"},{"key":"10.1016\/j.autrev.2024.103710_bb0275","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ncl.2020.09.006","article-title":"Advances in the management of small fiber neuropathy","volume":"39","author":"Zeidman","year":"2021","journal-title":"Neurol Clin"},{"key":"10.1016\/j.autrev.2024.103710_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109039","article-title":"Intravenouse immunoglobuline in dysautonomia","volume":"240","author":"Gavrilova","year":"2022","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2024.103710_bb0285","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.rmed.2017.03.011","article-title":"Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment","volume":"126","author":"Tavee","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.autrev.2024.103710_bb0290","series-title":"Miastenia gravis","author":"Est\u00e9vez","year":"2023"},{"key":"10.1016\/j.autrev.2024.103710_bb0295","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14737175.2022.2057223","article-title":"Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis","volume":"22","author":"Dalakas","year":"2022","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.autrev.2024.103710_bb0300","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/mus.27922","article-title":"Updated consensus statement: intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee","volume":"68","author":"Tavee","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2024.103710_bb0305","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2024.103710_bb0310","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","article-title":"Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome","volume":"47","author":"Bain","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2024.103710_bb0315","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200109","article-title":"Therapies in stiff-person syndrome: advances and future prospects based on disease pathophysiology","volume":"10","author":"Dalakas","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2024.103710_bb0320","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa01167","article-title":"High-dose intravenous immune globulin for stiff-person syndrome","volume":"345","author":"Dalakas","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103710_bb0325","first-page":"9","article-title":"Long-term effectiveness of IVIg maintenance therapy in 36 patients with GAD antibody-positive stiff-person syndrome","author":"Yi","year":"2022","journal-title":"Neurology(R) Neuroimmuno & Neuroinflammat"},{"key":"10.1016\/j.autrev.2024.103710_bb0330","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/acn3.51540","article-title":"The safety and efficacy of intravenous immunoglobulin in autoimmune encephalitis","volume":"9","author":"Lee","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.autrev.2024.103710_bb0335","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ana.25655","article-title":"Randomized placebo-controlled trial of intravenous immunoglobulin in autoimmune LGI1\/CASPR2 epilepsy","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2024.103710_bb0340","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1055\/a-1918-1824","article-title":"Diagnosis of Neuromyelitis Optica Spectrum disorder (NMOSD) and MOG antibody-associated disease (MOGAD)","volume":"239","author":"Mewes","year":"2022","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.autrev.2024.103710_bb0345","doi-asserted-by":"crossref","first-page":"E111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2024.103710_bb0350","first-page":"1","article-title":"Intravenous immunoglobulin as the rescue treatment in NMOSD patients","author":"Lin","year":"2021","journal-title":"Neurol Sci"},{"key":"10.1016\/j.autrev.2024.103710_bb0355","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1253\/circj.CJ-19-0773","article-title":"JCS 2017 guideline on management of vasculitis syndrome\u2014digest version\u2014","volume":"84","author":"Isobe","year":"2020","journal-title":"Circ J"},{"key":"10.1016\/j.autrev.2024.103710_bb0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international Chapel Hill consensus conference nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103710_bb0365","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103710_bb0370","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.24634","article-title":"American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2024.103710_bb0375","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/rheumatology\/kez311","article-title":"The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"59","author":"Shimizu","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2024.103710_bb0380","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejim.2023.06.021","article-title":"Intravenous immunoglobulin therapy in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"117","author":"Benavides-Villanueva","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.autrev.2024.103710_bb0385","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1007\/s00296-010-1518-y","article-title":"Takayasu\u2019s arteritis mimicking Kawasaki disease in 7-month-old infant, successfully treated with glucocorticosteroids and intravenous immunoglobulins","volume":"32","author":"Kierzkowska","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2024.103710_bb0390","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s10067-005-0015-2","article-title":"High-dose intravenous immunoglobulin infusion in polyarteritis nodosa: report on one case and review of the literature","volume":"25","author":"Asano","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2024.103710_bb0395","first-page":"187","article-title":"Intravenous immunoglobulin therapy in a child with cutaneous polyarteritis nodosa","volume":"16","author":"Uziel","year":"1998","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2024.103710_bb0400","unstructured":"Machet L, Vincent O, Machet M, \u2026 KB-\u2026 de D et al, 1995 undefined. Cutaneous periarteritis nodosa resistant to combined corticosteroids and immunosuppressive agents. Efficacy of treatment with intravenous immunoglobulins. EuropepmcOrgL Machet, O Vincent, MC Machet, K Barruet, L Vaillant, G LoretteAnnales de Dermatologie et de Venereologie, 1995\u2022europepmcOrg n.d."},{"key":"10.1016\/j.autrev.2024.103710_bb0405","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1445-5994.2012.02739.x","article-title":"Intravenous immunoglobulins as treatment of severe cutaneous polyarteritis nodosa","volume":"42","author":"Marie","year":"2012","journal-title":"Intern Med J"},{"key":"10.1016\/j.autrev.2024.103710_bb0410","first-page":"S28","article-title":"Intravenous immunoglobulins in polyarteritis nodosa restricted to the limbs: case reports and review of the literature","volume":"25","author":"Balbir-Gurman","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2024.103710_bb0415","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10238-022-00950-w","article-title":"Intravenous immunoglobulin therapy in immunoglobulin A vasculitis with gastrointestinal tract involvement","volume":"23","author":"\u00d6ner","year":"2023","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.autrev.2024.103710_bb0420","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1111\/pde.13715","article-title":"Successful treatment of hemorrhagic bullous Henoch-Schonlein purpura with intravenous immunoglobulins","volume":"36","author":"Mauro","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.autrev.2024.103710_bb0425","series-title":"The 4 Th Israel-ITaly MeeTIng efficacy and safety of intravenous immunoglobulin treatment in refractory Behcet\u2019s disease with different organ involvement: A case series","author":"Cantarini","year":"2024"},{"key":"10.1016\/j.autrev.2024.103710_bb0430","first-page":"14","article-title":"An overview of systemic lupus erythematosus (SLE) pathogenesis","author":"Ameer","year":"2022","journal-title":"Classificati Manag Cureus"},{"key":"10.1016\/j.autrev.2024.103710_bb0435","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/096120339700600412","article-title":"Successful treatment of early secondary myelofibrosis in SLE with IVIG","volume":"6","author":"Aharon","year":"1997","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2024.103710_bb0440","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s100670050079","article-title":"Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin","volume":"18","author":"Sherer","year":"1999","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2024.103710_bb0445","first-page":"388","article-title":"High dose intravenous immunoglobulins: a new step in the treatment of systemic lupus erythematosus","volume":"2","author":"Rauova","year":"2000","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.autrev.2024.103710_bb0450","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.autrev.2018.10.002","article-title":"Mechanisms of action and historical facts on the use of intravenous immunoglobulins in systemic lupus erythematosus","volume":"18","author":"Mart\u00ednez","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103710_bb0455","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000086","article-title":"Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: a systematic review and meta-analysis","volume":"93","author":"Sakthiswary","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2024.103710_bb0460","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1177\/0961203317696589","article-title":"Intravenous immunoglobulin: a biological corticosteroid-sparing agent in some autoimmune conditions","volume":"26","author":"Watad","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2024.103710_bb0465","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1177\/0961203319883680","article-title":"Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a single-center experience with 63 patients","volume":"28","author":"Nieto-Aristiz\u00e1bal","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2024.103710_bb0470","first-page":"21","article-title":"Efficacy and safety of intravenous immunoglobulin in patients with lupus nephritis: A systematic review of the literature","author":"Cajamarca-Bar\u00f3n","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103710_bb0475","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.semarthrit.2004.06.003","article-title":"Intravenous immunoglobulin and the kidney - A two-edged sword","volume":"34","author":"Orbach","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103710_bb0480","first-page":"391","article-title":"Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin","volume":"10","author":"Tomer","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2024.103710_bb0485","first-page":"1","article-title":"Neuropsychiatric lupus and lupus nephritis successfully treated with combined IVIG and rituximab: an alternative to standard of care","volume":"2022","author":"Cheikh","year":"2022","journal-title":"Case Rep Rheumatol"},{"key":"10.1016\/j.autrev.2024.103710_bb0490","first-page":"12","article-title":"Intravenous immunoglobulin in the Management of Lupus Erythematosus Panniculitis","author":"AlQadri","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.autrev.2024.103710_bb0495","first-page":"15","article-title":"Bullous systemic lupus erythematosus successfully treated with intravenous immunoglobulin and mycophenolate Mofetil","author":"Chow","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.autrev.2024.103710_bb0500","doi-asserted-by":"crossref","first-page":"SI46","DOI":"10.1093\/rheumatology\/kead556","article-title":"What we know and what we don\u2019t know about catastrophic antiphospholipid syndrome","volume":"63","author":"Rodriguez-Pint\u00f3","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2024.103710_bb0505","first-page":"22","article-title":"Low-dose intravenous immunoglobulin (IVIg) in different immune-mediated conditions","author":"Danieli","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103710_bb0510","first-page":"55","article-title":"Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases","volume":"10","author":"Sherer","year":"2008","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.autrev.2024.103710_bb0515","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clim.2018.12.006","article-title":"Intravenous immunoglobulin (IVIG) in the vanguard therapy of systemic sclerosis","volume":"199","author":"Gomes","year":"2019","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2024.103710_bb0520","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/art.10363","article-title":"The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice","volume":"46","author":"Blank","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2024.103710_bb0525","doi-asserted-by":"crossref","first-page":"103441","DOI":"10.1016\/j.autrev.2023.103441","article-title":"Immunoglobulins in systemic sclerosis management. A large multicenter experience","volume":"22","author":"Tandaipan","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103710_bb0530","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s100670050158","article-title":"Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin\u2013a preliminary report","volume":"19","author":"Levy","year":"2000","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2024.103710_bb0535","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/art.20195","article-title":"Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study","volume":"50","author":"Levy","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103710_bb0540","first-page":"13","article-title":"Intravenous immunoglobulins improve skin fibrosis in experimental models of systemic sclerosis","author":"Speca","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2024.103710_bb0545","first-page":"20","article-title":"Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from systematic literature review and from real life experience","author":"Agostini","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103710_bb0550","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12026-014-8615-z","article-title":"Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future","volume":"61","author":"Cantarini","year":"2015","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2024.103710_bb0555","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/rheumatology\/kev318","article-title":"Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis","volume":"55","author":"Raja","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2024.103710_bb0560","first-page":"42","article-title":"Efficacy of intravenous immunoglobulins in severe scleromyxedema dysphagia assessed by oesophageal scintigraphy","author":"Di Battista","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2024.103710_bb0565","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/1744666X.2022.2054803","article-title":"Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits","volume":"18","author":"Dalakas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2024.103710_bb0570","first-page":"12","article-title":"The value of intravenous immunoglobulin therapy in idiopathic inflammatory myositis in the current transformed era of biologics","author":"Patwardhan","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.autrev.2024.103710_bb0575","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11926-023-01105-w","article-title":"Intravenous immunoglobulin in idiopathic inflammatory myopathies: a practical guide for clinical use","volume":"25","author":"Gandiga","year":"2023","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2024.103710_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102997","article-title":"Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis","volume":"21","author":"Goswami","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103710_bb0585","doi-asserted-by":"crossref","first-page":"E23677","DOI":"10.1097\/MD.0000000000023677","article-title":"Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (\u201cProDERM study\u201d)","volume":"100","author":"Aggarwal","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2024.103710_bb0590","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103710_bb0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01401-z","article-title":"How we treat primary immune thrombocytopenia in adults","volume":"16","author":"Liu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.autrev.2024.103710_bb0600","first-page":"1","article-title":"Immune thrombocytopenia (ITP): current limitations in patient management","volume":"56","author":"Terrell","year":"2020","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.autrev.2024.103710_bb0605","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/17474086.2019.1636644","article-title":"Current and emerging treatments for immune thrombocytopenia","volume":"12","author":"Dou","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.autrev.2024.103710_bb0610","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.autrev.2024.103710_bb0615","first-page":"w13593","article-title":"Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases","volume":"142","author":"Imbach","year":"2012","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.autrev.2024.103710_bb0620","first-page":"839","article-title":"A possible role for IVIg in the treatment of soft tissue sarcoma: a clinical case and an experimental model","volume":"20","author":"Merimsky","year":"2002","journal-title":"Int J Oncol"},{"key":"10.1016\/j.autrev.2024.103710_bb0625","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3109\/08916934.2015.1104671","article-title":"Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: results of a prospective study including 167 cases","volume":"49","author":"Zhou","year":"2016","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2024.103710_bb0630","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/bjh.19072","article-title":"A proposal for new definition (s) and management approach to paediatric refractory ITP: reflections from the intercontinental ITP study group","volume":"203","author":"Neunert","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2024.103710_bb0635","first-page":"22","article-title":"Kawasaki Disease: an Update","author":"Rife","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2024.103710_bb0640","first-page":"2747","article-title":"Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young","volume":"110","author":"Newburger","year":"2004","journal-title":"American Heart Association Circulat"},{"key":"10.1016\/j.autrev.2024.103710_bb0645","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/1744666X.2017.1232165","article-title":"Kawasaki disease: etiopathogenesis and novel treatment strategies","volume":"13","author":"Agarwal","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2024.103710_bb0650","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00246-022-02973-2","article-title":"Association of Genetic Polymorphisms in Kawasaki disease with the response to intravenous immunoglobulin therapy","volume":"44","author":"Sapountzi","year":"2023","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.autrev.2024.103710_bb0655","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/MPG.0000000000000270","article-title":"Giant cell hepatitis with autoimmune hemolytic anemia in children: proposal for therapeutic approach","volume":"58","author":"Bakula","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.autrev.2024.103710_bb0660","doi-asserted-by":"crossref","DOI":"10.1111\/apa.12114","article-title":"Giant cell hepatitis with coombs-positive haemolytic anaemia: steroid sparing with high-dose intravenous immunoglobulin and cyclosporine","volume":"102","author":"Lega","year":"2013","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.autrev.2024.103710_bb0665","first-page":"6","article-title":"Giant cell hepatitis associated with autoimmune hemolytic anemia: an update. Transl","author":"Nastasio","year":"2021","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2024.103710_bb0670","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clinre.2015.03.009","article-title":"Efficacy of intravenous immunoglobulin therapy in giant cell hepatitis with autoimmune hemolytic anemia: A multicenter study","volume":"40","author":"Marsalli","year":"2016","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.autrev.2024.103710_bb0675","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2298\/VSP1311029M","article-title":"Use of intravenous immunoglobulin in neonates with haemolytic disease and immune thrombocytopenia","volume":"70","author":"Markovi\u0107-Sovti\u0107","year":"2013","journal-title":"Vojnosanit Pregl"},{"key":"10.1016\/j.autrev.2024.103710_bb0680","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.tmrv.2020.09.004","article-title":"Fetal and neonatal alloimmune thrombocytopenia\u2014new prospects for fetal risk assessment of HPA-1a\u2013negative pregnant women","volume":"34","author":"Kjeldsen-Kragh","year":"2020","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.autrev.2024.103710_bb0685","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/antib9040060","article-title":"Intravenous immune globulin uses in the fetus and neonate: a review","volume":"9","author":"Alsaleem","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.autrev.2024.103710_bb0690","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bjh.15813","article-title":"Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach","volume":"185","author":"Lieberman","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2024.103710_bb0695","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bpobgyn.2019.01.017","article-title":"Foetal and neonatal alloimmune thrombocytopenia","volume":"58","author":"Winkelhorst","year":"2019","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.autrev.2024.103710_bb0700","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2016-10-739656","article-title":"Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review","volume":"129","author":"Winkelhorst","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2024.103710_bb0705","first-page":"9","article-title":"Efficacy of intravenous immunoglobulin\/exchange transfusion therapy on gestational Alloimmune liver disease","author":"Yeh","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.autrev.2024.103710_bb0710","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/AOG.0000000000001569","article-title":"Gestational Alloimmune liver disease: A devastating condition preventable with maternal intravenous immunoglobulin","volume":"128","author":"Anastasio","year":"2016","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.autrev.2024.103710_bb0715","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.807173","article-title":"Molecular basis for global incidence of pemphigoid diseases and differences in phenotypes","volume":"13","author":"Ahmed","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103710_bb0720","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2317762121","article-title":"Restoring immune tolerance in pemphigus vulgaris","volume":"121","author":"Ahmed","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2024.103710_bb0725","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/exd.14829","article-title":"A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: special focus on indication and combination therapy","volume":"32","author":"Kianfar","year":"2023","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2024.103710_bb0730","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40257-020-00513-3","article-title":"A review comparing international guidelines for the Management of Bullous Pemphigoid, pemphigoid Gestationis, mucous membrane pemphigoid, and epidermolysis bullosa Acquisita","volume":"21","author":"Patel","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.autrev.2024.103710_bb0735","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jdermsci.2020.02.003","article-title":"SJS\/TEN 2019: from science to translation","volume":"98","author":"Chang","year":"2020","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.autrev.2024.103710_bb0740","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3390\/medicina57090895","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management","volume":"57","author":"Frantz","year":"2021","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.autrev.2024.103710_bb0745","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2020.08.122","article-title":"Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis","volume":"84","author":"Tsai","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2024.103710_bb0755","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1016\/S2666-5247(20)30144-0","article-title":"Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study","volume":"1","author":"Schurink","year":"2020","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.autrev.2024.103710_bb0760","first-page":"9","article-title":"Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA\/DNA SARS-CoV-2 vaccination","author":"Watad","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.autrev.2024.103710_bb0765","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A Meta-analysis","volume":"326","author":"Shankar-Hari","year":"2021","journal-title":"JAMA - J American Med Assoc"},{"key":"10.1016\/j.autrev.2024.103710_bb0770","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.transci.2016.12.017","article-title":"Mechanisms of action of intravenous immunoglobulin","volume":"56","author":"Chaigne","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.autrev.2024.103710_bb0775","first-page":"17","article-title":"Efficacy of intravenous immunoglobulin (IVIg) on COVID-19-related neurological disorders over the last 2 years: an up-to-date narrative review","author":"Manganotti","year":"2023","journal-title":"Front Neurosci"},{"key":"10.1016\/j.autrev.2024.103710_bb0780","first-page":"24","article-title":"Chronic inflammatory demyelinating polyneuropathy following COVID-19 vaccination: a case report and literature review","author":"Bahramy","year":"2024","journal-title":"BMC Neurol"},{"key":"10.1016\/j.autrev.2024.103710_bb0785","first-page":"238","article-title":"Guillain-Barr\u00e9 syndrome after COVID-19 vaccination: A systematic review and analysis of case reports","author":"Abuawwad","year":"2024","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.autrev.2024.103710_bb0790","first-page":"9","article-title":"Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA\/DNA SARS-CoV-2 vaccination","author":"Watad","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.autrev.2024.103710_bb0795","doi-asserted-by":"crossref","first-page":"1604501","DOI":"10.3389\/phrs.2022.1604501","article-title":"Long COVID through a public health lens: an umbrella review","volume":"43","author":"Nittas","year":"2022","journal-title":"Public Health Rev"},{"key":"10.1016\/j.autrev.2024.103710_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2024.08.008","article-title":"Current concepts in long-COVID brain fog and postural orthostatic tachycardia syndrome","author":"Tavee","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.autrev.2024.103710_bb0805","series-title":"Covid-19: US agency launches raft of clinical trials of treatments for long covid","author":"Tanne","year":"2023"},{"key":"10.1016\/j.autrev.2024.103710_bb0810","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10286-024-01020-9","article-title":"Randomized controlled trial of intravenous immunoglobulin for autoimmune postural orthostatic tachycardia syndrome (iSTAND)","volume":"34","author":"Vernino","year":"2024","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.autrev.2024.103710_bb0815","doi-asserted-by":"crossref","first-page":"1033651","DOI":"10.3389\/fimmu.2022.1033651","article-title":"Long-term high-dose immunoglobulin successfully treats long COVID patients with pulmonary, neurologic, and cardiologic symptoms","volume":"13","author":"Thompson","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103710_bb0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103230","volume":"22","author":"Malkova","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103710_bb0825","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2024.103710_bb0830","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial","volume":"62","author":"Gajdos","year":"2005","journal-title":"Arch Neurol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224002015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224002015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T19:06:48Z","timestamp":1734462408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224002015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":165,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1568997224002015"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103710","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous immunoglobulin as a therapy for autoimmune conditions","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103710","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103710"}}